Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Halt could last four more months...

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Jul 24, 2020 3:13pm

195 Views

Post# 31316178

RE:Halt could last four more months...

Thats for the Private Placement they just raised, Thats nothing to do with the stock halt itself. THis was halted because they didnt have the funds to complete the audit and pay for it, Now they have the money they just have to get the Filings completed and reapply to have the halt removed

TheQQMon wrote:

The Company expects that the FFCTO would be removed prior to the expiration of the customary hold period for private placement offerings that affect all issuers, in which case investors would not be subject to any hold periods beyond what is expected for all private placements.

2:55 PM
"Private placements of securities in Canada require a 4 month hold period " https://media2.mofo.com/documents/150203allthingscanadian.pdf